The UK Department of Health is currently evaluating tenders for a massive HPV vaccination program, pitting Merck's Gardasil against Cervarix. An anonymous source warns of an upcoming PR blitz as the companies compete for the government contract. The discussion highlights that these vaccines use "virus-like particles" (VLPs) and questions the long-term safety and necessity of injecting children with synthetic viral proteins.
